Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Change in Receivables (2016 - 2026)

Pharma-Bio Serv's Change in Receivables history spans 17 years, with the latest figure at $277116.0 for Q1 2026.

  • For Q1 2026, Change in Receivables rose 48.7% year-over-year to $277116.0; the TTM value through Jan 2026 reached -$112892.0, down 138.85%, while the annual FY2025 figure was -$203643.0, 86.02% up from the prior year.
  • Change in Receivables reached $277116.0 in Q1 2026 per PBSV's latest filing, down from $347839.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $663696.0 in Q2 2023 to a low of -$1.6 million in Q1 2024.
  • Average Change in Receivables over 5 years is -$74440.8, with a median of $186365.0 recorded in 2025.
  • The largest YoY upside for Change in Receivables was 489.17% in 2025 against a maximum downside of 4189.74% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$205939.0 in 2022, then plummeted by 650.94% to -$1.5 million in 2023, then skyrocketed by 94.22% to -$89380.0 in 2024, then soared by 489.17% to $347839.0 in 2025, then fell by 20.33% to $277116.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Change in Receivables are $277116.0 (Q1 2026), $347839.0 (Q4 2025), and -$675376.0 (Q3 2025).